Proteome alterations in MLL-rearranged leukemia cells following WIN Site inhibition

ABSTRACT: WIN Site inhibitors bind the WIN Site of WDR5 resulting in decreased transcription of WDR5 target genes, many of which encode components of the protein synthesis machinery. In this study, we determined proteome alterations in an MLL-rearranged leukemia cell line treated for either 24 or 72 hours with a WIN Site inhibitor. The data from these studies, along with Ribo-Seq, RNA-Seq, and CRISPR screen experiments, guided us in assembling a collection of compounds that, when combined with WIN Site inhibitor, synergistically inhibit growth of MLL-rearranged leukemia cells.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Acute Myeloid Leukemia Cell Line, Macrophage

DISEASE(S): Acute Myeloid Leukemia

SUBMITTER: Kristie Lindsey Rose  

LAB HEAD: Kristie Lindsey Rose

PROVIDER: PXD035129 | Pride | 2023-07-04

REPOSITORIES: Pride